175 related articles for article (PubMed ID: 31984655)
21. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE
Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
[TBL] [Abstract][Full Text] [Related]
22. Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea.
Brenner DM; Dove LS; Andrae DA; Covington PS; Gutman C; Chey WD
Neurogastroenterol Motil; 2018 Mar; ():e13331. PubMed ID: 29575372
[TBL] [Abstract][Full Text] [Related]
23. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea.
Lacy BE; Gagnon-Sanschagrin P; Heimanson Z; Bungay R; Bellefleur R; Guérin A; Bumpass B; Borroto D; Joseph G; Dashputre AA
Adv Ther; 2024 Jun; 41(6):2253-2266. PubMed ID: 38619720
[TBL] [Abstract][Full Text] [Related]
24. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
Jones J; Lembo A; Heidelbaugh J; Kuritzky L; Lacy B
Curr Med Res Opin; 2021 Apr; 37(4):567-578. PubMed ID: 33566707
[TBL] [Abstract][Full Text] [Related]
25. Τ Eluxadoline for IBS-D.
Drug Ther Bull; 2017 Aug; 55(8):91-92. PubMed ID: 28808082
[No Abstract] [Full Text] [Related]
26. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
[TBL] [Abstract][Full Text] [Related]
27. Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome.
Nee J; Salley K; Ludwig AG; Sommers T; Ballou S; Takazawa E; Duehren S; Singh P; Iturrino J; Katon J; Lee HN; Rangan V; Lembo AJ
Clin Transl Gastroenterol; 2019 Dec; 10(12):e00110. PubMed ID: 31800542
[TBL] [Abstract][Full Text] [Related]
28. Eluxadoline: First Global Approval.
Garnock-Jones KP
Drugs; 2015 Jul; 75(11):1305-10. PubMed ID: 26149369
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome-Diarrhea With or Without Bile Acid Diarrhea: Open-Label Study.
Vijayvargiya P; Breen-Lyles M; Nord SL; Maselli D; Busciglio I; Boinpally R; Muslin A; Carrothers TJ; Camilleri M
Dig Dis Sci; 2022 Aug; 67(8):3911-3921. PubMed ID: 35122592
[TBL] [Abstract][Full Text] [Related]
30. ▼ Eluxadoline for IBS-D.
Drug Ther Bull; 2017 Aug; 55(8):90-93. PubMed ID: 28808081
[TBL] [Abstract][Full Text] [Related]
31. Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.
Gawron AJ; Bielefeldt K
Clin Gastroenterol Hepatol; 2018 Mar; 16(3):378-384.e2. PubMed ID: 28804032
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH
Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635
[TBL] [Abstract][Full Text] [Related]
33. Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation.
Brenner DM; Sharma A; Rao SSC; Laitman AP; Heimanson Z; Allen C; Sayuk GS
Dig Dis Sci; 2024 May; 69(5):1731-1738. PubMed ID: 38594429
[TBL] [Abstract][Full Text] [Related]
34. Eluxadoline approved for irritable bowel syndrome with diarrhea.
Traynor K
Am J Health Syst Pharm; 2015 Jul; 72(13):1078. PubMed ID: 26092951
[No Abstract] [Full Text] [Related]
35. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Nee J; Zakari M; Lembo AJ
Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
[TBL] [Abstract][Full Text] [Related]
36. Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
Med Lett Drugs Ther; 2016 Jan; 58(1485):4-5. PubMed ID: 26714241
[No Abstract] [Full Text] [Related]
37. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.
Lacy BE; King J; Shortino D; Schaumburg C; Haag-Molkenteller C; Chey WD
Neurogastroenterol Motil; 2022 Dec; 34(12):e14448. PubMed ID: 35975404
[TBL] [Abstract][Full Text] [Related]
38. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective.
Vera I; Júdez FJ
Rev Esp Enferm Dig; 2017 Nov; 109(11):788-794. PubMed ID: 28747053
[TBL] [Abstract][Full Text] [Related]
39. Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials.
Lacy BE; Harris LA; Chang L; Lucak S; Gutman C; Dove LS; Covington PS; Lembo A
Therap Adv Gastroenterol; 2019; 12():1756284819841290. PubMed ID: 31019552
[TBL] [Abstract][Full Text] [Related]
40. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.
Tack J; Schumacher K; Tonini G; Scartoni S; Capriati A; Maggi CA;
Gut; 2017 Aug; 66(8):1403-1413. PubMed ID: 27196574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
